HB3087 amends Illinois law governing the sale and tracking of methamphetamine precursor products, primarily ephedrine and pseudoephedrine. The bill updates the Methamphetamine Precursor Control Act and the Methamphetamine Precursor Tracking Act to tighten pharmacy distribution rules, require electronic tracking of sales, and establish additional compliance and funding provisions for the statewide precursor tracking program administered by the Illinois State Police.
Among its substantive changes, the bill requires targeted methamphetamine precursors sold through pharmacies to be packaged in blister packs or unit-dose packets, stored behind the pharmacy counter, and dispensed only by licensed pharmacy personnel or their agents. It also reinforces age- and identification-verification requirements, confidentiality and retention rules for purchase logs, and limits on how much precursor product may be sold to one person in a day or over a 30-day period. The bill adds a manufacturer fee structure beginning October 1, 2025, for products containing methamphetamine precursors sold in or brought into Illinois, with nonpayment treated as a violation subject to penalties. It also preserves an exception for products available only by valid prescription.
The bill’s impact on state law is to expand and formalize Illinois’ existing anti-diversion framework for methamphetamine precursor chemicals. It increases regulatory obligations for pharmacies, retail distributors, pharmacists, pharmacy technicians, and manufacturers, while giving the Illinois State Police and the Central Repository greater oversight through electronic transaction reporting and fee-supported program funding. It also creates or reinforces misdemeanor, felony, and petty-offense penalties for violations by employees, pharmacies, and manufacturers.
The general sentiment reflected in the voting history appears strongly supportive and noncontroversial: the bill passed the House 115-0 and a Senate motion 57-0. No committee transcripts were provided, and there is no recorded opposition in the available materials. The unanimous votes suggest broad bipartisan agreement on the need to control diversion of precursor chemicals used to manufacture methamphetamine.
The main points of contention, based on the text itself, would likely center on compliance burdens and cost impacts for pharmacies and manufacturers, especially the new monthly fee requirement and the expanded reporting and packaging rules. However, no specific objections are documented in the available discussion or vote history. The bill also appears to balance enforcement with a limited accommodation for legitimate medical use and for certain identification situations, which may have helped reduce controversy.
HB3087 amends the Methamphetamine Precursor Control Act (720 ILCS 648/25) and the Methamphetamine Precursor Tracking Act (720 ILCS 649/15 and 30). It changes pharmacy handling rules for targeted methamphetamine precursors, strengthens purchase limits and identification checks, requires electronic transaction reporting to the Central Repository, authorizes manufacturer fees to support the tracking program, and updates penalties for violations by pharmacies, employees, and manufacturers. The bill takes effect upon becoming law.
The available voting history shows overwhelming support, with a 115-0 House vote and a 57-0 Senate motion. No committee testimony or recorded debate is provided, but the unanimous votes indicate the bill was viewed favorably and as a public-safety measure with little visible opposition.
No explicit contention is documented in the provided materials. Based on the bill text, the most likely areas of concern would be the added compliance duties for pharmacies, the new manufacturer fee requirement, and the operational burden of electronic tracking and recordkeeping. The bill’s supporters appear to prioritize methamphetamine diversion prevention and law-enforcement access to logs, while any potential critics would likely focus on administrative costs and burdens on legitimate retail and pharmaceutical operations.